Cyrex Laboratories

What Is Alzheimer's-Associated Immune Reactivity? Alzheimer's-Associated Immune Reactivity refers to a group of biomarkers that evaluate whether the immune system is producing antibodies against brain proteins, infections, environmental chemicals, and other substances that have been studied in relation to neuroinflammation, cognitive decline, and neurological health. This category is best known through Alzheimer's LINX™, a specialized blood test panel developed by Cyrex Laboratories. The panel measures immune reactivity to dozens of targets associated with brain function, blood-brain barrier integrity, microbial exposures, environmental factors, and dietary proteins. Importantly, a positive result does not diagnose Alzheimer's disease, dementia, or memory loss. Likewise, a normal result does not guarantee protection from future cognitive decline. These biomarkers measure immune responses, not the presence or absence of a neurological disease. Instead, the panel is designed to identify patterns of immune reactivity that may provide additional insight into factors that could influence brain health and cognitive function. What Alzheimer's LINX Does — and Does Not Measure One of the most common misconceptions about Alzheimer's-associated immune testing is that it functions as a diagnostic test for Alzheimer's disease. It does not. Alzheimer's disease is currently diagnosed using a combination of clinical evaluation, cognitive testing, imaging studies, cerebrospinal fluid biomarkers, and increasingly blood-based biomarkers such as phosphorylated tau and amyloid-related markers. Alzheimer's LINX evaluates whether the immune system is reacting to specific proteins, pathogens, environmental chemicals, or dietary antigens that researchers have investigated in connection with neuroinflammation and neurodegenerative processes. A positive result may indicate immune recognition of a target. It does not prove that the target is causing symptoms, nor does it establish that a person has Alzheimer's disease. Results should always be interpreted alongside medical history, symptoms, cognitive assessments, imaging findings, and other laboratory data. Why Immune Reactivity Matters in Brain Health Research increasingly suggests that Alzheimer's disease and other neurodegenerative disorders involve more than the accumulation of amyloid-beta plaques and tau tangles. Scientists are actively studying the roles of: Chronic inflammation Immune system activation Blood-brain barrier dysfunction Metabolic disease Environmental exposures Infections and microbial triggers Oxidative stress These factors may influence neurological health years before significant cognitive symptoms appear. The immune system plays a central role in many of these processes. When immune responses become chronic or dysregulated, they may contribute to inflammation within the nervous system and potentially affect neuronal function. Alzheimer's-associated immune reactivity testing is intended to explore whether immune responses against specific targets are present and whether they may warrant further investigation. What Does This Category Measure? The biomarkers in this category generally fall into several major groups. Brain Proteins Associated With Neurodegeneration These biomarkers assess immune reactivity to proteins that play important roles in brain structure and neurological function, including: Tau Protein Amyloid-Beta Peptide Alpha-Synuclein Rabaptin-5 + Presenilin These proteins have been extensively studied in Alzheimer's disease and other neurodegenerative conditions. Growth Factors and Neuroregeneration Markers This group evaluates immune responses directed against molecules involved in neuronal growth, repair, and maintenance, including: Brain-Derived Neurotrophic Factor (BDNF) Nerve Growth Factor (NGF) Neurotrophins Somatotropin These molecules help support neuronal survival, communication, and adaptability throughout life. Blood-Brain Barrier and Neural Integrity Markers The blood-brain barrier (BBB) serves as a protective interface between the bloodstream and the brain. Biomarkers in this category evaluate immune reactivity to proteins involved in maintaining BBB integrity and neural structure, including: Blood-Brain Barrier Protein + Claudin-5 Neurofilament Proteins Aquaporins Abnormal immune reactivity to these targets may suggest increased immune recognition of structures that normally help protect and support the nervous system. Pathogens and Microbial Triggers Researchers continue to investigate whether chronic infections and microbial exposures may contribute to neuroinflammation or cognitive decline in susceptible individuals. This category includes immune-reactivity markers associated with: Herpes Simplex Virus Type 1 (HSV-1) Oral pathogens Enterococcus faecalis Campylobacter jejuni Escherichia coli toxins Salmonella toxins The presence of antibodies reflects immune recognition and should not be interpreted as proof of active infection. Environmental Chemicals and Heavy Metals Environmental exposures may influence oxidative stress, inflammation, and immune activation. Biomarkers in this category evaluate immune reactivity to substances such as: Aluminum Mercury compounds Phthalates Dinitrophenyl-related compounds These tests do not directly measure toxic burden. Instead, they assess whether the immune system has developed antibodies against compounds associated with environmental exposure. Food Cross-Reactivity Markers Some biomarkers evaluate foods that have been studied for potential immune cross-reactivity with neurological proteins and amyloid-related targets. Examples include: Caseins Gliadin-related proteins Egg yolk proteins Lentil and pea lectins Selected seafood proteins Tree nut proteins Importantly, positive food-reactivity findings do not prove that a food is causing neurological symptoms, cognitive decline, or Alzheimer's disease. These results are best viewed as hypothesis-generating markers that may warrant further discussion with a qualified healthcare professional. Who May Consider Alzheimer's-Associated Immune Reactivity Testing? Healthcare professionals may consider this type of testing for individuals who: Have a family history of Alzheimer's disease or dementia Are experiencing memory concerns or cognitive changes Have autoimmune or chronic inflammatory conditions Have a history of traumatic brain injury or repeated head trauma Have gastrointestinal disorders associated with immune dysregulation Are interested in exploring potential contributors to neuroinflammation Are following a preventive or functional medicine approach to cognitive health Testing is generally intended to provide additional information rather than establish a diagnosis. How Are Results Typically Used? Results may help identify areas for further investigation, including: Immune responses to neurological proteins Blood-brain barrier integrity concerns Chronic inflammatory patterns Environmental exposure considerations Dietary immune-reactivity patterns Potential microbial triggers Healthcare professionals may integrate these findings with other laboratory results, imaging studies, cognitive assessments, and clinical history to develop a broader understanding of an individual's neurological health profile. Bottom Line Alzheimer's-Associated Immune Reactivity testing evaluates immune responses directed against brain proteins, blood-brain barrier structures, pathogens, environmental chemicals, and dietary antigens that have been studied in relation to neuroinflammation and cognitive health. These biomarkers do not diagnose Alzheimer's disease, dementia, or memory loss. Instead, they provide information about immune-reactivity patterns that may help identify potential contributors to neurological health concerns and guide further clinical investigation. For individuals exploring potential contributors to cognitive health, Alzheimer's LINX™ and related biomarkers provide one additional lens—alongside established neurological assessment, imaging, and validated biomarkers—for understanding immune-reactivity patterns that may be relevant to brain health.

Written By: B. Dame Updated On: January 27, 2025 Comprehensive Guide to IgG Food Sensitivity Testing: A Key Tool for Managing Food-Related Symptoms What is an IgG Food Sensitivity Test? This test is a comprehensive food immune reactivity assessment, evaluating 180 foods in the form they are typically consumed—whether raw, cooked, or both. By measuring Immunoglobulin G (IgG) antibody responses to these foods, the test provides actionable insights into potential food sensitivities and immune reactions. How Does IgG Food Sensitivity Affect the Body? Elevated IgG antibody levels can trigger an inflammatory response, which may lead to tissue damage and a range of symptoms. While the antibodies themselves do not cause harm, their role in initiating inflammation can contribute to: Gastrointestinal distress (e.g., bloating, gas, diarrhea) Neurological issues (e.g., headaches, fatigue) Skin problems (e.g., rashes, itching) Respiratory symptoms (e.g., nasal congestion, asthma) It’s important to note that IgG reactivity does not always correlate directly with symptoms. However, elimination of reactive foods has been shown to reduce these symptoms significantly in many cases. The Importance of IgG Food Sensitivity Testing IgG food testing is a valuable tool for individuals with chronic conditions, including: Neurological disorders (e.g., epilepsy, ADHD, autism spectrum disorders) Gastrointestinal disorders (e.g., irritable bowel syndrome, Crohn’s disease, celiac disease) Autoimmune conditions (e.g., rheumatoid arthritis) Metabolic concerns (e.g., obesity, diabetes) The test helps guide elimination diets, which have been clinically proven to alleviate symptoms associated with food sensitivities. For example: A study reported a 71% success rate in symptom improvement after patients eliminated IgG-reactive foods. Commonly improved symptoms included fatigue, headaches, chronic coughing, asthma, rashes, diarrhea, and nasal congestion. IgG vs. IgE: Understanding the Difference Food-related immune reactions are broadly categorized into IgG-mediated sensitivities and IgE-mediated allergies: IgE Food Allergies: Immediate hypersensitivity reactions (e.g., hives, anaphylaxis). Triggered by the release of histamine, often within minutes of eating the offending food. IgG Food Sensitivities: Delayed hypersensitivity reactions, with symptoms appearing hours or days later. Caused by inflammation from IgG food antigen-antibody complexes binding to complement. Benefits of IgG Food Testing for Symptom Management Elimination diets based on IgG test results have demonstrated success in improving conditions such as: Irritable Bowel Syndrome (IBS): Reduced symptoms like bloating, diarrhea, and rectal discomfort. Migraines: Decreased frequency and severity of headaches. Celiac and Non-Celiac Gluten Sensitivity: Symptom relief through gluten-free diets. Autism Spectrum Disorders (ASD): Behavioral improvements linked to dietary changes. Epilepsy: Reduced seizures and hyperkinetic behavior. Cystic Fibrosis: Improved growth rates and reduced gastrointestinal symptoms. Rheumatoid Arthritis: Alleviation of inflammation-related pain. The Role of Elimination Diets Elimination diets guided by IgG food test results can help pinpoint specific food triggers and improve overall well-being. Research has shown these diets to: Decrease stool frequency in Crohn’s disease. Improve kidney function in glomerulonephritis. Reduce atopic symptoms, such as eczema and respiratory issues. Enhance behaviors in children with ADHD. Clinical Evidence Supporting IgG Food Testing Clinical studies have consistently demonstrated the effectiveness of IgG-guided elimination diets: 93% of non-celiac gluten-sensitive patients showed significant improvement in gastrointestinal and extra-intestinal symptoms after adhering to a gluten-free diet for six months. High IgG antibody levels have been frequently observed in individuals with diabetes mellitus, obesity, Crohn’s disease, and celiac disease, highlighting the potential link between food sensitivities and chronic health conditions. Key Takeaways Elevated IgG reactivity to certain foods doesn’t always indicate intolerance, but elimination diets can significantly reduce symptoms in many cases. Symptoms like headaches, skin issues, fatigue, and digestive discomfort are often improved by removing IgG-reactive foods. IgG food testing provides a valuable tool for managing chronic conditions and optimizing health. Frequently Asked Questions (FAQs) 1. What does an elevated IgG level mean? Elevated IgG levels suggest an immune response to specific foods but don’t necessarily indicate intolerance. It’s a marker of potential sensitivity, and elimination diets can help determine if symptoms improve by avoiding those foods. 2. How long do IgG food antibodies stay in the body? IgG antibodies can remain in the body for several weeks, which is why symptoms of IgG food sensitivities may appear hours to days after consuming the triggering food. 3. What conditions can IgG food testing help with? IgG food testing has been shown to benefit conditions like IBS, migraines, autism spectrum disorders, ADHD, rheumatoid arthritis, and epilepsy. 4. How is IgG different from IgE testing? IgE testing identifies immediate food allergies, while IgG testing identifies delayed food sensitivities that cause symptoms over time. Both play distinct roles in understanding immune reactions to food. 5. Can IgG food testing help with weight loss? While not directly designed for weight loss, identifying and removing IgG-reactive foods may help reduce inflammation and improve energy levels, supporting overall health and weight management. 6. How accurate is IgG food sensitivity testing? IgG food testing is supported by research and clinical evidence, but results should always be interpreted by a qualified healthcare provider. Combining test results with elimination diets often yields the best outcomes. Find out more about the Elimination diet here >>

Array 11 measures an expanded range of environmental chemical toxins that bind to human tissues versus other laboratory tests that only identify chemical exposure. Clinical Use: - Identify the loss of immune tolerance associated with chemical exposure, which may lead to autoimmune reactivity - Assist in setting guidelines for the avoidance of specific chemicals to reduce the risk of igniting the autoimmune process - Monitor the effectiveness of the clinical management of patients

Array 12 – Pathogen-Associated Immune Reactivity Screen assesses IgG immune reactivity to pathogens that are documented triggers or exacerbators of autoimmunity. Array 12 contains a variety of pathogens including oral pathogens, gastrointestinal pathogens, gastrointestinal parasites, bacterial and stealth pathogens, environmental molds, viral pathogens and tick-borne pathogens. - Tick-borne pathogens are obvious triggers of Lyme disease, however there are additional pathogens that haven’t been in the limelight. - One example is the opportunistic bacterium Acinetobacter, which, due to cross-reactivity with neurological tissues, has been shown to play a role in multiple sclerosis. - Giardia lamblia is well known as a cause of watery diarrhea, but less known for persisting in asymptomatic patients where the pathogen destroys intestinal villa thereby preventing nutrient absorption. Giardia can then cross-react with structural proteins such as tubulin and actin, which then triggers autoimmunity of the joints.

Array 14 - Multiple Mucosal Immune Reactivity Screen (Cyrex Laboratories) is a cost-effective, easy, and non-invasive method for measuring mucosal immune reaction to a range of exogenous and endogenous antigens. The production of IgA and IgM antibodies against antigens in saliva may be an early stage in the induction of inflammation and autoimmunity. If the immune reactivity is not addressed and it may result in a breach of the intestinal barrier, followed by a systemic immune reaction. The inflammation of systemic autoantibodies contributes to the progression of autoimmune and neuroautoimmune reactivity. Array 14 was developed based on the immunological occurrence that exposure to an antigen via the mouth and intestinal tract results first in the production of IgA antibodies in secretions. Repeated exposure to the same antigen(s) results in the production of IgG, IgM and IgA antibodies in the blood. The biomarkers in Array 14 were selected to give an invaluable picture of both likely antigens which may cause immune reactions and the areas they may effect. These include the following: Commonly consumed foods such as wheat, lectins, milk, soy, corn and egg Gut microbiota-associated toxins Toxic chemicals that contaminate food and form neoantigens with food proteins, such as aflatoxin, bisphenol-A and heavy metals Rotavirus, which is involved in GI inflammation and the induction of food immune reactivity and autoimmunity Tight junction/structural proteins involved in leaky gut and inflammation Crohn’s disease and ulcerative colitis biomarkers such as ASCA, ANCA and calprotectin Enzymes such as transglutaminase-2 that are involved in celiac disease and non-celiac gluten sensitivity Enteric nerve/neural antigens such as myelin basic protein and S100B (BBB) because enteric nerve cells can be damaged by inflammation in the gut. Similar to CNS astrocytes, enteric glia cells express S100B, which is responsible for the maintenance of inflammation in the gut. Immune complexes can be formed by triggers such as bacterial antigens, viral antigens, mold antigens, xenobiotics, dietary components, and associated tissue antigens, which further contribute to the entry of antigens, immune complexes, or other inflammatory molecules into the submucosa, and then into circulation. Due to structural similarity between the intestinal barrier and blood-brain barrier (BBB), these IgA + IgM antibodies, immune complexes and inflammatory signals can also affect the integrity of the BBB resulting in autoimmunity against nervous system tissues, both in the gut and the brain.

This test measures intestinal permeability to large molecules, which inflame the immune system. Gluten can cause silent inflammation in the gut, which can eventually lead to intestinal permeability, or “leaky gut.” Also, NSAID medications, chronic stress, excess alcohol, proton pump inhibitors and other factors can also contribute to “leaky gut” which allows undigested food particles, bacteria, and other antigens to escape into the bloodstream where they can trigger allergies, sensitivities, and inflammation in various parts of the body. This test helps to determine if leaky gut is present and can be used to monitor complete healing of the gut lining. For an interpretative chart, please visit our blog entry called "Guide to Intestinal antigenic permeability screen (Cyrex Screen 2)".

Cyrex Laboratories' Array 20 measures antibodies against proteins of the blood-brain barrier. This barrier is the layer of tightly joined cells that controls what passes from the blood into the brain. It reports two results: blood-brain barrier protein IgG+IgA, and blood-brain barrier protein IgM. What the test aims to show: Raised antibodies are intended to suggest the immune system has been exposed to barrier proteins. Cyrex presents this as a sign that the barrier may be more permeable than normal. The antibody class does not show when an immune response, or any change in the barrier, began. How to read the results: This is a specialty test. It has limited independent validation and is not part of standard neurological workups. A raised result does not diagnose a specific brain condition, and a normal result does not rule one out. Results are best discussed with a clinician who knows the test, alongside symptoms and other findings.

-- Identify the overgrowth of large intestinal bacteria in the small intestine and the release of bacterial cytotoxins -- Evaluate a breach of intestinal barrier by bacterial cytotoxins and their entry into circulation -- Assist in setting guidelines for treatment of irritable bowels/SIBO and reduce risk of igniting the autoimmune process Recommended for Patients Who: -- Have irritable bowels -- Exhibit symptoms of malabsorption, including weight loss, anemia or fatty stools -- Have associated conditions such as fatigue, reflux, skin disorders, obesity or food intolerances

Inclusion of the specific antigens comprising Antibody Array 3, or Comprehensive Gluten Reactivity and Autoimmunity is based on recent medical research studies. Comprehensive quantitative mapping of T-cell epitopes was determined in CD. Results demonstrated that people respond to a heterogeneous array of peptides; some recognized many peptides from single or multiple gliadin families, while others reacted to only one peptide. These results confirmed that a large number of gluten epitopes may be implicated in the development of CD and associated diseases. Indeed, a T-cell line from one Celiac patient failed to recognize any of the 21 tested peptides, which confirmed that a large number of gluten and other wheat protein epitopes are implicated in development of CD and associated disorders. This suggests that other gliadin peptides and proteins are involved in the pathogenesis of Gluten-Reactivity and CD. Cyrex extended this heterogeneity in T-cell responses to gluten and other peptides originated from wheat to humoral immune responses by measuring IgG and IgA antibodies against nine different wheat antigens and peptides as well as enzymes associated with autoimmunities. Heterogeneity in IgG and IgA antibodies against these twelve antigens was confirmed by variation in antibody response against various wheat associated antigens on individual bases. Measuring a patient’s immune response to an array of wheat antigens increases the sensitivity and specificity, and will provide greater confidence in formulation of a diagnosis that allows for better patient compliance with a gluten-free diet. Assessing wheat/gluten reactivity and intestinal autoimmunity is recommended for people who: - Have gut dysbiosis, which appears to be resistant to standard therapy - Are suspected of having intestinal mucosal damage - Complain of food allergy and intolerance - Complain of chemical hypersensitivity - Present multiple-symptom complaints (including Chronic Fatigue Syndrome and Fibromyalgia) - Suffer from abnormal immune cell count and function - May suffer from blood-brain barrier permeability, depression, or neuroautoimmunity - Neuroautoimmune patients to consider: - Thyroiditis - Arthritis - Myocarditis - Dermatitis - Endocrinopathy - Polyendocrinopathy - Osteoarthritis - Pernicious Anemia - Other Clinical Use: - Identify possible Celiac disease, non-celiac gluten sensitivity, dermatitis herpetiformis, gluten ataxia or other wheat/gluten-related disorder. - Assess autoimmune reactivity associated with wheat proteins and peptides. What is celiac disease? Celiac disease is a well-recognized medical condition in which gliadins (gluten proteins found in wheat, barley and rye) cause an immune reaction in sensitive individuals which destroys the lining of the small intestine. This can lead to severe digestive symptoms and malabsorption of nutrients However, some celiac patients have no gut symptoms, even though their body is still being damaged, while others experience neurological and psychiatric symptoms instead of the classic digestive distress. It is now recognized that many people have reactions to either wheat or gluten that don’t qualify as a celiac disease but still impact on their health. This includes wheat sensitivity and non-celiac gluten-sensitivity. Previously it was thought that the effects of gluten were limited to celiac disease, and strictly gut-oriented, such as bloating, gas, and abdominal pain. What are common symptoms of celiac disease, wheat sensitivity and non-celiac gluten sensitivity? The symptoms of celiac disease, wheat sensitivity and NCGS are very diverse. This can make it difficult to diagnose and it is not possible to distinguish between different gluten-related complaints on the basis of symptoms alone. Common symptoms include: - Bloating - Abdominal pain - Fatigue - Diarrhoea or constipation - Headaches - Anxiety - Depression - Nausea - Brain fog - Heartburn - Numbness in arms and legs - Ataxia (lack of coordination, gait abnormality, speech changes or abnormalities in eye movements) - Mouth ulcers - Joint and muscle pain - Dermatitis/rashes - Anaemia Older tests for celiac disease and gluten sensitivity focus on just one protein – alpha gliadin. It has been discovered wheat is made up of more than 100 different components that can cause a reaction, not just one. The problem is, a person can react to only one of the many proteins in wheat, or a combination of proteins, peptides, and enzymes associated with wheat. The full range of antigens tested includes: - Wheat IgG - Wheat IgA - Wheat Germ Agglutinin IgG - Wheat Germ Agglutinin IgA - Non-Gluten Proteins-A IgG* - Non-Gluten Proteins-A IgA* - Non-Gluten Proteins-B IgG* - Non-Gluten Proteins-B IgA* - Gliadin Toxic Peptides IgG* - Gliadin Toxic Peptides IgA* - Native + Deamidated Alpha-Gliadin-33-mer IgG - Native + Deamidated Alpha-Gliadin-33-mer IgA - Alpha-Gliadin-17-mer IgG - Alpha-Gliadin-17-mer IgA - Gamma-Gliadin-15-mer IgG - Gamma-Gliadin-15-mer IgA - Omega-Gliadin-17-mer IgG - Omega-Gliadin-17-mer IgA - Glutenin-21-mer IgG - Glutenin-21-mer IgA - Gluteomorphin+Prodynorphin IgG - Gluteomorphin+Prodynorphin IgA - Gliadin-Transglutaminase Complex IgG - Gliadin-Transglutaminase Complex IgA - Microbial Transglutaminase IgG* - Microbial Transglutaminase IgA* - Transglutaminase-2 IgG - Transglutaminase-2 IgA - Transglutaminase-3 IgG - Transglutaminase-3 IgA - Transglutaminase-6 IgG - Transglutaminase-6 IgA The test is able to identify possible celiac disease, non-celiac gluten sensitivity, dermatitis herpetiformis, gluten ataxia or other wheat/gluten-related disorders. It can also be useful for assessing autoimmune reactivity associated with wheat proteins and peptides. How to interpret your test results? When IgA reactions are predominant, it is an indication of possible Celiac disease and other autoimmunities. When IgG reactions are predominant, it is an indication of wheat/gluten immune response and possible autoimmunity due to lack of digestive enzymes and/or other factors.When both IgA and IgG reactions occur, it is an indication of wheat/gluten immune response and its progression to Celiac disease and/or other autoimmune disorders. For an interpretive chart, please visit out blog: https://blog.healthmatters.io/2023/07/03/cyrex-3-interpretation-chart/

Many times, gluten-free foods, which are supposed to be safe, can be offensive to some individuals. This can be due to sensitivity or a phenomenon called Cross-Reactivity. Once a patient is diagnosed as Celiac Disease (CD) or having Gluten Reactivity, he/she is instructed to adhere to a gluten-free diet. Brochures, books and websites help the patient with this seemingly difficult process. However, a significant percentage of these patients will continue to have gluten-like complaints even after being on a gluten-free diet (GFD) for months. Most countries define “gluten-free” products based on the recommendation of the Food and Agricultural Organization of the United Nations and World Health Organization. This codex alimentarius allows the inclusion of up to 0.3% protein from gluten containing grains in foods labeled “gluten-free.” If the sensitive body is exposed to 0.3% protein, the immune system will recognize and react to the protein. Testing for Gluten-Associated Cross-Reactive Foods and Foods Sensitivity in this array can assist the clinician in revealing the possible cause of this continued gluten-like reaction in the patient. Recommended for patients who: - Have Non-Celiac Gluten Sensitivity or Celiac disease. - Are experiencing limited improvements or are non-responsive on a gluten-free diet. - Have gut dysbiosis, which appears to be resistant to standard therapy

Predictive Autoantibody Testing: Early Detection of Autoimmune and Tissue Damage This test measures predictive autoantibodies, including some that may appear up to 10 years before clinical symptoms. It provides a cost-effective and efficient evaluation of potential tissue damage across multiple organs, empowering early diagnosis and intervention for autoimmune and related conditions. Clinical Applications: Early Autoimmune Detection: Measures predictive antibodies that can emerge up to a decade before disease onset. Comprehensive Tissue Health Assessment: Efficiently and economically identifies possible damage to multiple organs. Recommended for: Patients With Diagnosed Autoimmune Disorders: These individuals are at a higher risk of developing additional autoimmune conditions. Individuals With Chronic Increased Intestinal Permeability ("Leaky Gut"): A known gateway for environmentally triggered autoimmune diseases. Antigens Tested: IgG Markers: Thyroglobulin Thyroid Peroxidase (TPO) Autoantibodies: Islet Cell Antigen (IA-2) Glutamic Acid Decarboxylase 65 (GAD 65) Combined IgG + IgA Markers: Parietal Cell + ATPase Intrinsic Factor ASCA + ANCA Tropomyosin 21 Hydroxylase (Adrenal Cortex) Myocardial Peptide Alpha-Myosin Phospholipid Platelet Glycoprotein Ovary/Testis* Fibulin Collagen Complex Arthritic Peptide Osteocyte Cytochrome P450 (Hepatocyte) Myelin Basic Protein Asialoganglioside Alpha + Beta Tubulin Cerebellar Synapsin By offering predictive autoantibody testing alongside targeted antigen panels, this test empowers individuals and healthcare providers to take a proactive approach to autoimmune health and organ function.

Comprehensive Lymphocyte Immunophenotyping: A Breakthrough in Immune System Analysis FEATURES Unique Immunotypes for Comprehensive Insights The panel includes 14 immunotypes designed to uncover critical immune system trends by analyzing a wide range of determinants. Advanced Th1/Th2 Balance Analysis (Immunotypes 6 & 7) Utilizes the proprietary Cyrex Fluorescence-Activated Cell Test (Cyrex FACT™) to assess T-helper-1 (Th1) and T-helper-2 (Th2) dominance. Unlike traditional methods that measure cytokine levels, Cyrex FACT™ analyzes specific CD markers on the surface of Th1 and Th2 cells, offering a more precise and actionable insight into immune balance. Regulatory T Cells (Tregs, Immunotype 8) Evaluates Tregs, essential for maintaining the balance between Th1 and Th2 responses. Low Treg levels can contribute to issues such as immune suppression, autoimmune disorders, increased infections, and cancer. Th17 Dominance (Immunotype 9) Includes a specialized Cyrex FACT™ process to identify Th17 dominance via CD markers, avoiding reliance on IL-17 blood levels for a more accurate depiction of immune dynamics. Natural Killer (NK) Cell Patterns (Immunotypes 12 & 13) Identifies imbalances in NK cells, cytotoxic NK cells, and NK T cells, which are vital for targeting pathogens and cancer cells. CD57+ NK Cells and Their Role (Immunotype 14) Evaluates CD57+ NK cells, long-lived immune cells critical for targeting infected and cancerous cells, particularly in aging populations. High levels of CD57+ NK cells are linked to better outcomes in cancer and autoimmune diseases, while low levels may indicate reduced survival rates. CLINICAL USES Immune System Assessment: Evaluates the immune system's cellular integrity to detect weaknesses or imbalances. Pre-Disease Detection: Identifies abnormalities before disease onset, enabling early intervention. Personalized Treatment Design: Guides the creation of customized treatment protocols during active disease stages. Treatment Monitoring: Tracks patient recovery and medication effectiveness post-treatment. Why Choose the Lymphocyte MAP™ by Cyrex Laboratories? The Lymphocyte MAP™ is an advanced, comprehensive diagnostic panel designed to assess the immune system's functionality and integrity at the cellular level. By analyzing 29 key lymphocyte biomarkers, including Th1, Th2, Treg, Th17, and various NK cell types, this test provides a detailed overview of immune health. Key features include: The use of Cyrex FACT™, a cutting-edge process for precise immune profiling. The ability to detect immune deficiencies, inflammation, autoimmunity, allergies, asthma, and cancer at the cellular level. This test is ideal for: Proactive health optimization for individuals seeking to enhance longevity and resilience. Patients with autoimmune diseases, chronic infections, or inflammation, such as those with post-viral syndromes or COVID-19 exposure. By providing healthcare practitioners with actionable insights, the Lymphocyte MAP™ supports tailored treatment strategies to restore immune balance and improve patient outcomes. Maximize your immune health with the Lymphocyte MAP™ by Cyrex Laboratories—the gold standard in immune system evaluation.